Ekso Bionics Appoints Howard Palefsky to its Board of Directors
March 23 2017 - 8:00AM
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton
company, today announced that Howard Palefsky has been appointed to
its board of directors, effective immediately.
Howard Palefsky is a veteran in the healthcare industry who has
extensive experience as an entrepreneur, CEO, board chair, director
and investor in the life sciences, including medical devices.
Mr. Palefsky is currently an active advisor or board member to
multiple companies in the healthcare arena, including Olatec
Therapeutics, Adigica Health, Life Sciences Alternative Funding and
Victoria Capital Management. Previously, he was a managing
director at Montreux Equity Partners as well as chairman and CEO of
a Montreux portfolio company, NeurogesX. From 1978 to 1997,
Mr. Palefsky was the chairman, president and CEO of Collagen
Corporation, a pioneer in the aesthetic medicine field. Mr.
Palefsky led Collagen from a pre-revenue, venture funded start up
through numerous financings, product approvals, international
launches and profitability, all of which culminated in Collagen’s
initial public offering. He then managed the creation of
Collagen’s spin-off companies and each of their ultimate
acquisitions.
“We are delighted to be adding Howard to our board. He has
a proven track record of operational excellence and organizational
development at medical device companies,” said Thomas Looby,
president and chief executive officer of Ekso Bionics. “His
experience and leadership will be vital as we continue
growing.”
“I am honored and delighted to be part of a company that can
change lives the way that Ekso Bionics’ exoskeletons can, and I am
very excited about the prospects for Ekso’s technologies to enable
spinal cord injury and stroke patients to regain function,” said
Mr. Palefsky. “I look forward to working with management and the
board to build on the great work already done as the company
continues on its upward trajectory.”
About Ekso Bionics®Ekso Bionics is a leading
developer of exoskeleton solutions that amplify human potential by
supporting or enhancing strength, endurance and mobility across
medical, industrial and defense applications. Founded in 2005, the
company continues to build upon its unparalleled expertise to
design some of the most cutting-edge, innovative wearable robots
available on the market. Ekso Bionics is the only exoskeleton
company to offer technologies that range from helping those with
paralysis to stand up and walk, to enhancing human capabilities on
job sites across the globe, to providing research for the
advancement of R&D projects intended to benefit U.S. defense
capabilities. The company is headquartered in the Bay Area and is
listed on the Nasdaq Capital Market under the symbol EKSO. For more
information, visit: www.eksobionics.com.
About Ekso GT™Ekso GT™ is the first exoskeleton
cleared by the FDA for use with stroke and spinal cord injuries
from L5 to C7. The EksoGT with SmartAssist™ software is the only
exoskeleton available for rehabilitation institutions that can
provide adaptive amounts of power to either side of the patient’s
body, challenging the patient as they progress through their
continuum of care. The suit’s patented technology provides the
ability to mobilize patients earlier, more frequently and with a
greater number of high intensity steps. To date, this device has
helped patients take more than 70 million steps in over 130
rehabilitation institutions around the world.
Forward-Looking StatementsAny statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements. Forward-looking
statements may include, without limitation, statements regarding
(i) the plans and objectives of management for future operations,
including plans or objectives relating to the design, development
and commercialization of human exoskeletons, (ii) estimates or
projection of financial results, financial condition, capital
expenditures, capital structure or other financial items, (iii) the
Company's future financial performance and (iv) the assumptions
underlying or relating to any statement described in points (i),
(ii) or (iii) above. Such forward-looking statements are not meant
to predict or guarantee actual results, performance, events or
circumstances and may not be realized because they are based upon
the Company's current projections, plans, objectives, beliefs,
expectations, estimates and assumptions and are subject to a number
of risks and uncertainties and other influences, many of which the
Company has no control over. Actual results and the timing of
certain events and circumstances may differ materially from those
described by the forward-looking statements as a result of these
risks and uncertainties. Factors that may influence or contribute
to the inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may
include, without limitation, the Company's inability to obtain
adequate financing to fund the Company's operations and necessary
to develop or enhance our technology, the significant length of
time and resources associated with the development of the Company's
products, the Company's failure to achieve broad market acceptance
of the Company's products, the failure of our sales and marketing
organization or partners to market our products effectively,
adverse results in future clinical studies of the Company's medical
device products, the failure to obtain or maintain patent
protection for the Company's technology, failure to obtain or
maintain regulatory approval to market the Company's medical
devices, lack of product diversification, existing or increased
competition, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC. To learn more about Ekso Bionics please visit us at
www.eksobionics.com. The Company does not undertake to update these
forward-looking statements.
Media Contact:
Carrie Yamond
917-371-2320
cyamond@lazarpartners.com
Investor Contact:
Debbie Kaster
415-937-5403
investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Sep 2023 to Sep 2024